ATE449869T1 - Verfahren zur beurteilung der wirksamkeit von chemotherapeutika - Google Patents

Verfahren zur beurteilung der wirksamkeit von chemotherapeutika

Info

Publication number
ATE449869T1
ATE449869T1 AT03779093T AT03779093T ATE449869T1 AT E449869 T1 ATE449869 T1 AT E449869T1 AT 03779093 T AT03779093 T AT 03779093T AT 03779093 T AT03779093 T AT 03779093T AT E449869 T1 ATE449869 T1 AT E449869T1
Authority
AT
Austria
Prior art keywords
methods
assessing
chemotherapeutic
effectiveness
chemotherapeutics
Prior art date
Application number
AT03779093T
Other languages
English (en)
Inventor
Paul Kornblith
Sean Mcdonald
Original Assignee
Precision Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Therapeutics Inc filed Critical Precision Therapeutics Inc
Application granted granted Critical
Publication of ATE449869T1 publication Critical patent/ATE449869T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03779093T 2002-10-10 2003-10-10 Verfahren zur beurteilung der wirksamkeit von chemotherapeutika ATE449869T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41743902P 2002-10-10 2002-10-10
US10/336,659 US20040072722A1 (en) 2002-10-10 2003-01-02 Methods for assessing efficacy of chemotherapeutic agents
PCT/US2003/032285 WO2004035833A1 (en) 2002-10-10 2003-10-10 Methods for assessing efficacy of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
ATE449869T1 true ATE449869T1 (de) 2009-12-15

Family

ID=32072939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03779093T ATE449869T1 (de) 2002-10-10 2003-10-10 Verfahren zur beurteilung der wirksamkeit von chemotherapeutika

Country Status (6)

Country Link
US (4) US20040072722A1 (de)
EP (1) EP1556515B1 (de)
AT (1) ATE449869T1 (de)
AU (1) AU2003285866A1 (de)
DE (1) DE60330266D1 (de)
WO (1) WO2004035833A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023375A1 (en) * 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20070087401A1 (en) * 2003-10-17 2007-04-19 Andy Neilson Analysis of metabolic activity in cells using extracellular flux rate measurements
US8658349B2 (en) 2006-07-13 2014-02-25 Seahorse Bioscience Cell analysis apparatus and method
US7042565B2 (en) * 2004-02-13 2006-05-09 Kaiwood Technology Co., Ltd. Fluorescent microarray analyzer
WO2007028146A2 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CA2680528A1 (en) * 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
EP2207892A4 (de) 2007-10-15 2010-12-08 Precision Therapeutics Inc Verfahren zur selektion aktiver agentien für die krebsbehandlung
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US8202702B2 (en) * 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US20110097748A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Use of cell lines to determine levels of efficacy of pharmaceutical formulations
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2771043A4 (de) 2011-10-28 2015-04-29 Presage Biosciences Inc Wirkstofffreisetzungsverfahren
CN104471052B (zh) 2012-11-13 2017-06-13 海马生物科学公司 用于基于控制介质流动的三维组织测量的装置和方法
CA2895791A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
DE102013010528B3 (de) * 2013-06-25 2014-02-20 FLACOD GmbH Verfahren zur Erstellung einer Datenbank für die Vorabschätzung der Wirksamkeit von Wirkstoffen in der Tumortherapie
EP3689467B1 (de) 2014-06-02 2025-04-09 Agilent Technologies, Inc. Mikroplattenträger zur analyse biologischer proben
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
US9566012B2 (en) 2014-10-27 2017-02-14 Medtronic, Inc. Method and apparatus for selection and use of virtual sensing vectors
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423145A (en) * 1981-05-07 1983-12-27 Stampfer Martha R Enhanced growth medium and method for culturing human mammary epithelial cells
US4668618A (en) 1981-09-14 1987-05-26 Thornthwaite Jerry T Nuclear isolation medium and procedure for separating cell nuclei
US4559299A (en) * 1983-02-04 1985-12-17 Brown University Research Foundation Inc. Cytotoxicity assays in cell culturing devices
US4937187A (en) * 1983-02-04 1990-06-26 Brown University Research Foundation Methods for separating malignant cells from clinical specimens
US4816395A (en) * 1985-12-19 1989-03-28 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US4996145A (en) * 1987-10-27 1991-02-26 Oncotech Incorporated Method for detecting immune-mediated cytotoxicity
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5407653A (en) * 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
EP0610441A4 (de) * 1991-10-29 1996-01-10 Clover Cons Ltd Vernetzbare polysacchariden, polykationen und lipiden verwendbar zum einkapseln und abgabe von arzneimitteln.
WO1994000470A1 (en) 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
GB9419716D0 (en) 1994-09-30 1994-11-16 Gearey David Electrochemical assessment of cell behaviour and metabolic activity
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5888765A (en) 1995-06-23 1999-03-30 President And Fellows Of Harvard College Endothelial-cell specific promoter
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US20040023375A1 (en) * 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US20020168679A1 (en) * 1998-06-11 2002-11-14 Gregory J. Naus Staining agents and protocols for characterizing malignant cells in culture
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US6416967B2 (en) * 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US6008007A (en) * 1997-01-31 1999-12-28 Oncotech, Inc. Radiation resistance assay for predicting treatment response and clinical outcome
US5840507A (en) * 1997-03-19 1998-11-24 Oncotech, Inc. Methods for cancer prognosis and diagnosis
US5972639A (en) * 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US6074874A (en) 1997-08-29 2000-06-13 University Of Pittsburgh Epithelial cell cultures for in vitro testing
US6111092A (en) * 1998-06-03 2000-08-29 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding DRT111 and uses thereof
US6664062B1 (en) * 1998-07-20 2003-12-16 Nuvelo, Inc. Thymidylate synthase gene sequence variances having utility in determining the treatment of disease
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
EP1059352A1 (de) 1999-06-08 2000-12-13 Oncodia AG Langzeitkultur humaner Karzinome
EP1283904A2 (de) * 1999-11-03 2003-02-19 Oncotech, Inc. Diagnose von krebs mit zellsortierung und genexpressionsprofilen
WO2001035316A2 (en) * 1999-11-10 2001-05-17 Structural Bioinformatics, Inc. Computationally derived protein structures in pharmacogenomics
AU2001240998A1 (en) * 2000-03-06 2001-09-17 Technion Research And Development Foundation Ltd. Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy
ATE526423T1 (de) * 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
AU2002224435A1 (en) 2000-10-18 2002-04-29 Precision Therapeutics, Inc. Method for tandem genomic/proteomic analyses of proliferating cells
DE60234440D1 (de) * 2001-01-12 2009-12-31 Univ Washington Mdr1-varianten und verfahren zu ihrer verwendung
US20040086888A1 (en) 2001-10-18 2004-05-06 Kornblith Paul L Method for tandem genomic/proteomic analysis of proliferating cells
JP3923366B2 (ja) * 2001-10-24 2007-05-30 財団法人癌研究会 細胞の抗癌剤感受性の判定法
US7767390B2 (en) * 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
WO2007028146A2 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics

Also Published As

Publication number Publication date
US7575868B2 (en) 2009-08-18
DE60330266D1 (de) 2010-01-07
US20080032298A1 (en) 2008-02-07
WO2004035833A1 (en) 2004-04-29
EP1556515A4 (de) 2007-11-07
US20090286255A1 (en) 2009-11-19
AU2003285866A1 (en) 2004-05-04
EP1556515B1 (de) 2009-11-25
EP1556515A1 (de) 2005-07-27
US8039213B2 (en) 2011-10-18
US7829288B2 (en) 2010-11-09
US20110020826A1 (en) 2011-01-27
US20040072722A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
DE60330266D1 (de) Verfahren zur beurteilung der wirksamkeit von chemotherapeutika
DE602004027761D1 (de) Verfahren zum Auswählen und Aufnehmen von Tierzellenkolonien
ATE484231T1 (de) Vorrichtung für vorhersage von muskel/skelett- erkrankungen
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
ATE441857T1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
WO2007072225A8 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1774039A4 (de) Genetische marker zur vorhersage des krankheits- und behandlungsausgangs
EP1774043A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
DE602004027070D1 (de) Verfahren und vorrichtung zum positionieren beim ersatz von anoden in einer elektrolysezelle
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
FI20031366L (fi) Menetelmä anodiliejun käsittelemiseksi
CY1110138T1 (el) Προσδιορισμος υψηλης διεκπεραιωτικοτητας της δραστικοτητας lp-pla2
WO2005006949A3 (en) Methods for predicting development of auto-immune diseases and treatment of same
EA200800951A1 (ru) Устройство и способ для оценивания ценностного показателя рабочего процесса и определения разрывов в текущем и желаемом состояниях
WO2013077814A3 (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
ATE488763T1 (de) Verfahren zur identifizierung von sich auf einen zellzustand auswirkenden bedingungen
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
TW200501988A (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
ATE358673T1 (de) Nf-kb-inhibitoren
ATE400814T1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties